Patent 7750116 was granted and assigned to Seagen on July, 2010 by the United States Patent and Trademark Office.
Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided. Also provided are antibody drug conjugate metabolites.